Vera Therapeutics Secures FDA BLA Priority Review
Vera Therapeutics announced on January 7 that the U.S. Food and Drug Administration accepted Atacicept's Biologics License Application for priority review to treat adult immunoglobulin A nephropathy, with a target action date of July 7, 2026. ORIGIN 3 data showed a 46% decline in proteinuria and a 42% reduction in urine protein-to-creatinine ratio at week 36 versus placebo, and approval would enable once-weekly at-home injections as the first B-cell modulator targeting APRIL and BAFF.
Key Points
- 1Announces FDA acceptance of Atacicept BLA for IgAN with July 7, 2026 action date
- 2Reports ORIGIN 3 efficacy: 46% proteinuria decline and 42% urine protein-to-creatinine reduction
- 3Enables potential once-weekly at-home injections and first APRIL/BAFF dual B-cell modulator therapy
Scoring Rationale
Strong regulatory milestone and Phase 3 efficacy increase value, limited by company-specific scope and non-AI relevance.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
